RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the recharge feature of the Activa RC System in patients who are receiving Deep Brain Stimulation (DBS) for Parkinson's Disease (PD), Essential Tremor (ET), or dystonia.

Official Title
-----------------
RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)

Conditions
-----------------
Parkinson's Disease, Essential Tremor, Dystonia

Intervention / Treatment
-----------------
* Device: Activa RC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is enrolled in the Implantable Systems Performance Registry (ISPR) and will receive one Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for DBS. Patient must meet the indications in the Activa RC labeling. Patient (or patient's legally authorized representative) signs and dates the appropriate RECHARGE Informed Consent Form and/or Informed Assent Form and Authorization to Use and Disclose Health Information (HIPAA, US only). Patient has a diagnosis of Parkinson's Disease, Essential Tremor, or dystonia that meets the approved indication for Activa RC in the applicable geography. Patient with dystonia is 7 years of age or older (EU only). Patient with either PD or ET is 18 years of age or older. Patient (or caregiver) is able to use the patient programmer and correctly interpret the icons. Patient (or caregiver) is able and willing to regularly monitor the status of the rechargeable battery and respond appropriately. Patient (or caregiver) is able to locate the INS, position the recharge antenna for sufficient coupling, put on the recharge holster/belt, and monitor progress during the recharge session. Patient (or caregiver) is able to perform recharging activities for sufficient duration and frequency to maintain therapy and to perform recharging activities on an ongoing basis. Patient is willing and able to comply with protocol requirements. Exclusion Criteria: Patient has a contraindication identified in the Activa RC labeling. Patient who is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of the RECHARGE study. Patient has or will be implanted with a non-Medtronic Deep Brain Stimulation system component.

Ages Eligible for Study
-----------------
Minimum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients receiving an Activa RC implant<br> | Device: Activa RC<br>* Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify the Rate of User-related Battery Depletion Adverse Events Per Subject-month Requiring Intervention by a Health Care Professional (HCP) and/or the HCP's Designee, Within the First 3 Months of the Activa RC System Being Turned ON. | Subject-months of follow-up were defined as the time from device activation to the earlier of a subject's 3-month visit or until the subject exited from the study. Any user-related battery depletion adverse events requiring intervention by a health care professional (HCP) and/or the HCP's designee were collected. The event rate per 100 subject-months of follow-up is defined as the number of user-related battery depletion events divided by the total subject follow-up months through the 3-month visit, all multiplied by 100. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, Essential Tremor, Dystonia (where indication is approved), Deep brain stimulation, Activa RC